Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:10:49.858Z.
Calculation as of: 2026-10-06T20:10:49.858Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a536da8eae666eb645f8b33c150b74020e4e9b3ff535c5becd935f4d76daa57
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$16.74M
Price/FCF Ratio
N/A
TTM Avg
2103.03
3Y Avg
2594.52
5Y Avg
2594.52
Market Cap
$16.52M
Price/FCF Ratio
N/A
TTM Avg
43.53
3Y Avg
55.71
5Y Avg
97.87
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bionano Genomics, Inc. (BNGO) | $16.64M | N/A | N/A | N/A | N/A |
| PAVmed Inc. (PAVM)vs › | $16.72M | N/A | N/A | N/A | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | N/A | 2103.03 | 2594.52 | 2594.52 |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | N/A | 43.53 | 55.71 | 97.87 |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | N/A | N/A | N/A | N/A |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A | 14.41 | 40.25 | 40.25 |
| BioCardia, Inc. (BCDA)vs › | $15.78M | N/A | 121.92 | 75.43 | 64.77 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
